HRP20120477T1 - Nova anti plgf protutijela - Google Patents
Nova anti plgf protutijela Download PDFInfo
- Publication number
- HRP20120477T1 HRP20120477T1 HRP20120477TT HRP20120477T HRP20120477T1 HR P20120477 T1 HRP20120477 T1 HR P20120477T1 HR P20120477T T HRP20120477T T HR P20120477TT HR P20120477 T HRP20120477 T HR P20120477T HR P20120477 T1 HRP20120477 T1 HR P20120477T1
- Authority
- HR
- Croatia
- Prior art keywords
- image
- artificial sequence
- antigen
- dna
- misc
- Prior art date
Links
- 102100035194 Placenta growth factor Human genes 0.000 claims abstract 9
- 239000012634 fragment Substances 0.000 claims abstract 4
- 230000002265 prevention Effects 0.000 claims abstract 2
- 239000000427 antigen Substances 0.000 claims 18
- 102000036639 antigens Human genes 0.000 claims 18
- 108091007433 antigens Proteins 0.000 claims 18
- 108091034117 Oligonucleotide Proteins 0.000 claims 12
- 241000699660 Mus musculus Species 0.000 claims 10
- 108010082093 Placenta Growth Factor Proteins 0.000 claims 8
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 3
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 claims 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 150000001413 amino acids Chemical group 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000035699 permeability Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 abstract 1
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 abstract 1
- 208000034038 Pathologic Neovascularization Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Surgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66476805P | 2005-03-24 | 2005-03-24 | |
PCT/BE2006/000023 WO2006099698A2 (en) | 2005-03-24 | 2006-03-24 | Novel anti-plgf antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20120477T1 true HRP20120477T1 (hr) | 2012-07-31 |
Family
ID=36928446
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20120477TT HRP20120477T1 (hr) | 2005-03-24 | 2012-06-06 | Nova anti plgf protutijela |
Country Status (27)
Country | Link |
---|---|
US (3) | US7875704B2 (de) |
EP (2) | EP1869085B1 (de) |
JP (2) | JP5164829B2 (de) |
KR (1) | KR101314014B1 (de) |
CN (1) | CN101184776B (de) |
AT (1) | ATE549358T1 (de) |
AU (2) | AU2006227571B8 (de) |
BR (1) | BRPI0609151B8 (de) |
CA (1) | CA2601267C (de) |
CY (1) | CY1113224T1 (de) |
DK (1) | DK1869085T3 (de) |
EA (1) | EA013970B1 (de) |
ES (2) | ES2565481T3 (de) |
HK (1) | HK1116803A1 (de) |
HR (1) | HRP20120477T1 (de) |
IL (1) | IL185754A (de) |
ME (1) | ME01446B (de) |
MX (1) | MX2007011735A (de) |
NO (1) | NO341877B1 (de) |
NZ (1) | NZ561763A (de) |
PL (1) | PL1869085T3 (de) |
PT (1) | PT1869085E (de) |
RS (1) | RS52372B (de) |
SI (1) | SI1869085T1 (de) |
UA (1) | UA94707C2 (de) |
WO (1) | WO2006099698A2 (de) |
ZA (1) | ZA200707258B (de) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE321069T1 (de) * | 2000-05-12 | 2006-04-15 | Vlaams Interuniv Inst Biotech | Verwendung von inhibitoren des plazenta wachstumsfactors für die behandlung einer pathologischen angiogenese, pathologischen arteriogenese, entzündung, tumorbildung und/oder gefässdurchlässigkeit (ödem) |
CN101184776B (zh) | 2005-03-24 | 2013-04-24 | 斯路姆基因公司 | 新型抗胎盘生长因子抗体 |
CN101534865A (zh) * | 2005-10-19 | 2009-09-16 | Ibc药品公司 | 生物活性装配体的制备方法及其用途 |
AU2009241589B2 (en) | 2008-04-29 | 2013-10-10 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
EP3002299A1 (de) | 2008-06-03 | 2016-04-06 | AbbVie Inc. | Dual-variable- domain-immunglobuline und ihre verwendungen |
MX2010013236A (es) | 2008-06-03 | 2011-02-24 | Abbott Lab | Inmunoglobulinas de dominio variable doble y usos de las mismas. |
MX2010014574A (es) | 2008-07-08 | 2011-04-27 | Abbott Lab | Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas. |
KR101798664B1 (ko) | 2008-10-02 | 2017-11-16 | 브이아이비 브이지더블유 | 필라델피아 염색체 양성 백혈병의 치료를 위한 피엘지에프의 억제 |
CA2746120A1 (en) * | 2008-12-23 | 2010-07-01 | Genentech, Inc. | Methods and compositions for diagnostic use in cancer patients |
EP2424566A4 (de) * | 2009-05-01 | 2013-07-31 | Abbvie Inc | Immunglobuline mit zweifacher variabler domäne und ihre verwendung |
PE20121530A1 (es) | 2009-09-01 | 2012-12-22 | Abbvie Inc | Inmunoglobulinas con dominio variable dual |
US8716450B2 (en) | 2009-10-15 | 2014-05-06 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
WO2011110598A1 (en) | 2010-03-10 | 2011-09-15 | F. Hoffmann-La Roche Ag | Method for purifying immunoglobulin solutions |
ES2560219T3 (es) * | 2010-07-19 | 2016-02-17 | F. Hoffmann-La Roche Ag | Biomarcadores del plasma sanguíneo para terapias de combinación con bevacizumab para el tratamiento del cáncer pancreático |
RU2013109275A (ru) | 2010-08-03 | 2014-09-10 | Эббви Инк. | Иммуноглобулины с двумя вариабельными доменами и их применение |
KR20130139884A (ko) | 2010-08-26 | 2013-12-23 | 애브비 인코포레이티드 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
ES2628321T3 (es) | 2011-12-01 | 2017-08-02 | Thrombogenics N.V. | Mejora del resultado de una trabeculectomía |
TW201333035A (zh) | 2011-12-30 | 2013-08-16 | Abbvie Inc | 針對il-13及/或il-17之雙特異性結合蛋白 |
RU2017137740A (ru) | 2012-11-01 | 2019-02-11 | Эббви Инк. | Анти-vegf/dll4-иммуноглобулины с двойными вариабельными доменами и их применения |
ES2929942T3 (es) | 2012-12-18 | 2022-12-05 | Icahn School Med Mount Sinai | Vacunas contra el virus de la gripe y sus usos |
WO2014159960A1 (en) | 2013-03-14 | 2014-10-02 | Icahn School Of Medicine At Mount Sinai | Antibodies against influenza virus hemagglutinin and uses thereof |
BR112015023797A2 (pt) | 2013-03-15 | 2017-10-24 | Abbvie Inc | proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17 |
US10035847B2 (en) | 2013-10-02 | 2018-07-31 | The Rockefeller University | Amyloid protofibril antibodies and methods of use thereof |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
AU2016209032A1 (en) | 2015-01-23 | 2017-08-10 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccination regimens |
TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
CN104930353B (zh) * | 2015-07-10 | 2017-08-15 | 浙江大学 | 一种城市供水管网的调压减漏评估系统 |
CA3013808A1 (en) | 2016-03-10 | 2017-09-14 | Thrombogenics Nv | Posterior ocular fibrosis inhibition by antagonizing placental growth factor |
BR112018075032A2 (pt) | 2016-06-15 | 2019-03-26 | Icahn School Of Medicine At Mount Sinai | proteínas de hemaglutinina do vírus influenza e seus uso |
US11254733B2 (en) | 2017-04-07 | 2022-02-22 | Icahn School Of Medicine At Mount Sinai | Anti-influenza B virus neuraminidase antibodies and uses thereof |
CN109134650A (zh) * | 2018-09-10 | 2019-01-04 | 宁波奥丞生物科技有限公司 | 抗人plgf单克隆抗体的制备方法 |
US20220220197A1 (en) | 2019-05-28 | 2022-07-14 | Vib Vzw | Cancer Treatment by Targeting Plexins in the Immune Compartment |
WO2020239934A1 (en) | 2019-05-28 | 2020-12-03 | Vib Vzw | Cd8+ t-cells lacking plexins and their application in cancer treatment |
WO2020260595A1 (en) | 2019-06-26 | 2020-12-30 | Oncurious Nv | Combination treatment of medulloblastoma using a placental growth factor inhibitor and a chemotherapeutic agent |
EP3936868A1 (de) | 2020-07-10 | 2022-01-12 | Charité - Universitätsmedizin Berlin | Verhältnis zwischen plgf und sflt1, das prädiktiv für die neurale invasion bei patienten mit pankreaskrebs ist |
WO2022063957A1 (en) | 2020-09-24 | 2022-03-31 | Vib Vzw | Biomarker for anti-tumor therapy |
CN112358546B (zh) * | 2020-11-10 | 2022-04-01 | 宁波奥丞生物科技有限公司 | 杂交瘤细胞株9c1、plgf-1单克隆抗体及其应用 |
WO2022099465A1 (zh) * | 2020-11-10 | 2022-05-19 | 宁波奥丞生物科技有限公司 | 杂交瘤细胞株9c1、plgf-1单克隆抗体及其制备方法和应用 |
JP2023554520A (ja) | 2020-12-22 | 2023-12-27 | コビオレス エヌヴイ | テトラペプチド部分を含む化合物 |
CN113999310A (zh) * | 2020-12-30 | 2022-02-01 | 江苏普若维生物技术有限责任公司 | 一种plgf单克隆抗体、试剂盒、其制备方法和应用 |
WO2022167664A1 (en) | 2021-02-07 | 2022-08-11 | Cobiores Nv | Compounds comprising a tetrapeptidic moiety |
US20240130999A1 (en) | 2021-02-17 | 2024-04-25 | Vib Vzw | Inhibition of SLC4A4 in the Treatment of Cancer |
WO2023118294A1 (en) | 2021-12-22 | 2023-06-29 | Vib Vzw | Inhibition of mitoferrin 2 as means for inhibiting cancer and cancer metastasis |
WO2024033381A1 (en) | 2022-08-10 | 2024-02-15 | Vib Vzw | Inhibition of tcf4/itf2 in the treatment of cancer |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
US5770198A (en) | 1988-05-18 | 1998-06-23 | The Research Foundation Of The State Of New York | Platelet-specific chimeric 7E3 immunoglobulin |
US5545806A (en) * | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
IT1242149B (it) * | 1990-09-27 | 1994-02-16 | Consiglio Nazionale Ricerche | Sequenza di nucleotidi codificante per una proteina umana con proprieta' regolative dell'angiogenesi |
US5578704A (en) * | 1992-04-03 | 1996-11-26 | Genentech, Inc. | Antibody to osteoclast alphavbeta3 ntegrin |
US6177401B1 (en) * | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
US5861499A (en) * | 1994-02-10 | 1999-01-19 | Imclone Systems Incorporated | Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain |
IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
KR19990066967A (ko) | 1995-10-23 | 1999-08-16 | 둘헌티 브리안 | 비정상적인 망막 혈관형성을 치료하기 위한 유전자 치료법과vegf 안티센스용 dna 운반체로써 사용되는 히알루론산 |
ES2274549T3 (es) | 1996-09-24 | 2007-05-16 | MERCK & CO., INC. | Compuestos para la inhibicion de la angiogenesis por terapia de genes . |
US6986890B1 (en) * | 1996-11-21 | 2006-01-17 | Kyowa Hakko Kogyo Co., Ltd. | Anti-human VEGF receptor Flt-1 monoclonal antibody |
GB9723780D0 (en) | 1997-11-12 | 1998-01-07 | Univ Manchester | Regulation of ocular angiogenesis |
DK2016951T3 (da) * | 1998-03-17 | 2012-09-24 | Genentech Inc | VEGF- og BMP1-homologe polypeptider |
JPH11302193A (ja) * | 1998-04-22 | 1999-11-02 | Toagosei Co Ltd | 血管新生阻害剤 |
WO1999060846A1 (en) | 1998-05-26 | 1999-12-02 | Innogenetics N.V. | Method for expanding primate b cells selectively in immunocompromised mice and producing large numbers of antigen-specific b lymphocytes for the production of primate monoclonal antibodies |
JP2001086982A (ja) | 1999-07-16 | 2001-04-03 | Shunpei Niida | 骨吸収調節薬 |
CA2399022A1 (en) * | 2000-02-04 | 2001-08-09 | Supratek Pharma Inc. | Ligand for vascular endothelial growth factor receptor |
ATE321069T1 (de) | 2000-05-12 | 2006-04-15 | Vlaams Interuniv Inst Biotech | Verwendung von inhibitoren des plazenta wachstumsfactors für die behandlung einer pathologischen angiogenese, pathologischen arteriogenese, entzündung, tumorbildung und/oder gefässdurchlässigkeit (ödem) |
JP2005515157A (ja) * | 2001-05-25 | 2005-05-26 | トマス ジェファソン ユニバーシティ | 多様な治療様式のための主成分としての選択的スプライスフォーム |
US7139817B1 (en) * | 2001-06-12 | 2006-11-21 | Network Appliance, Inc. | Managing configuration information for multiple devices |
US20040247597A1 (en) | 2001-06-20 | 2004-12-09 | Peter Carmeliet | Method of treating atherosclerosis and other inflammatory diseases |
DE60310383T2 (de) | 2002-01-29 | 2007-09-20 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. | Vorbeugung von gewebeadhäsion |
WO2003103581A2 (en) | 2002-06-05 | 2003-12-18 | Genentech, Inc. | Compositions and methods for liver growth and liver protection |
EP1517703B1 (de) * | 2002-06-28 | 2007-03-21 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Plazenta-wachstumsfaktor als target für die behandlung von osteoporose |
AU2003279621A1 (en) * | 2002-11-08 | 2004-06-07 | Primagen Holding B.V. | Method for quantifying a ratio between at least two nucleic acid sequences |
EP1610806A4 (de) * | 2003-03-10 | 2006-04-19 | Callisto Pharmaceuticals Inc | Verfahren zur behandlung von krebs mit azaspiran-zusammensetzungen |
US20050282233A1 (en) * | 2004-03-05 | 2005-12-22 | Ludwig Institute For Cancer Research | Multivalent antibody materials and methods for VEGF/PDGF family of growth factors |
CN101184776B (zh) * | 2005-03-24 | 2013-04-24 | 斯路姆基因公司 | 新型抗胎盘生长因子抗体 |
WO2007003609A1 (en) | 2005-06-30 | 2007-01-11 | Vib Vzw | Treatment of liver cirrhosis and its complications |
KR101798664B1 (ko) | 2008-10-02 | 2017-11-16 | 브이아이비 브이지더블유 | 필라델피아 염색체 양성 백혈병의 치료를 위한 피엘지에프의 억제 |
-
2006
- 2006-03-24 CN CN2006800093279A patent/CN101184776B/zh not_active Expired - Fee Related
- 2006-03-24 EA EA200702064A patent/EA013970B1/ru not_active IP Right Cessation
- 2006-03-24 ES ES11160897.2T patent/ES2565481T3/es active Active
- 2006-03-24 WO PCT/BE2006/000023 patent/WO2006099698A2/en active Application Filing
- 2006-03-24 RS RS20120249A patent/RS52372B/en unknown
- 2006-03-24 EP EP06721544A patent/EP1869085B1/de active Active
- 2006-03-24 DK DK06721544.2T patent/DK1869085T3/da active
- 2006-03-24 ES ES06721544T patent/ES2384110T3/es active Active
- 2006-03-24 US US11/909,604 patent/US7875704B2/en not_active Expired - Fee Related
- 2006-03-24 UA UAA200711730A patent/UA94707C2/ru unknown
- 2006-03-24 CA CA2601267A patent/CA2601267C/en not_active Expired - Fee Related
- 2006-03-24 ZA ZA200707258A patent/ZA200707258B/xx unknown
- 2006-03-24 PL PL06721544T patent/PL1869085T3/pl unknown
- 2006-03-24 JP JP2008502194A patent/JP5164829B2/ja not_active Expired - Fee Related
- 2006-03-24 MX MX2007011735A patent/MX2007011735A/es active IP Right Grant
- 2006-03-24 EP EP11160897.2A patent/EP2447281B1/de not_active Not-in-force
- 2006-03-24 NZ NZ561763A patent/NZ561763A/en unknown
- 2006-03-24 KR KR1020077024317A patent/KR101314014B1/ko active IP Right Grant
- 2006-03-24 BR BRPI0609151A patent/BRPI0609151B8/pt not_active IP Right Cessation
- 2006-03-24 AT AT06721544T patent/ATE549358T1/de active
- 2006-03-24 AU AU2006227571A patent/AU2006227571B8/en not_active Ceased
- 2006-03-24 SI SI200631343T patent/SI1869085T1/sl unknown
- 2006-03-24 ME MEP-2012-73A patent/ME01446B/me unknown
- 2006-03-24 PT PT06721544T patent/PT1869085E/pt unknown
-
2007
- 2007-09-05 IL IL185754A patent/IL185754A/en active IP Right Grant
- 2007-09-10 NO NO20074563A patent/NO341877B1/no not_active IP Right Cessation
-
2008
- 2008-03-11 HK HK08102805.3A patent/HK1116803A1/xx not_active IP Right Cessation
-
2010
- 2010-12-20 US US12/973,155 patent/US8758748B2/en active Active
-
2011
- 2011-03-23 AU AU2011201340A patent/AU2011201340B2/en not_active Ceased
-
2012
- 2012-02-01 JP JP2012019698A patent/JP2012136522A/ja active Pending
- 2012-06-06 HR HRP20120477TT patent/HRP20120477T1/hr unknown
- 2012-06-12 CY CY20121100535T patent/CY1113224T1/el unknown
-
2014
- 2014-02-03 US US14/170,997 patent/US9085617B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20120477T1 (hr) | Nova anti plgf protutijela | |
JP5909442B2 (ja) | ヒト化axl抗体 | |
JP2018527903A5 (de) | ||
JP5981347B2 (ja) | Pcsk9アンタゴニスト | |
CN109517067B (zh) | 一种抗人rankl抗体、其人源化抗体及它们的药物组合物和用途 | |
JP2019536470A5 (de) | ||
KR102554634B1 (ko) | L1cam에 결합하는 신규한 결합 분자 특히 항체(cd171) | |
HRP20181087T1 (hr) | Pripravak i postupak dijagnostike i liječenja bolesti povezanih s degeneracijom neurita | |
WO2015191934A2 (en) | Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases | |
JP2013091655A5 (de) | ||
RU2014122990A (ru) | Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas | |
JP2014503202A (ja) | TNF−α結合性タンパク質 | |
JP2011509245A5 (de) | ||
TW201323441A (zh) | 抗tnf之雙特異性免疫結合物 | |
JP2015504421A5 (de) | ||
RU2018104283A (ru) | Антитела против ингибитора пути тканевого фактора и их применения | |
JP7469284B2 (ja) | アクチビン2型受容体結合タンパク質及びその使用 | |
JP2016503817A (ja) | アンチグラニュリシン抗体及びその使用方法 | |
CN109721656B (zh) | 靶向rankl的治疗性抗体 | |
EA036490B1 (ru) | Антитела, связывающиеся с tfpi, и содержащая их композиция | |
SG192047A1 (en) | Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins | |
TW202241944A (zh) | 新穎的抗gremlin1抗體 | |
JP2018531625A5 (de) | ||
KR20220129030A (ko) | 항-Gal3 항체 및 사용 방법 | |
JP2022548646A (ja) | 抗幹細胞因子抗体及びその使用方法 |